Rigvir group has signed a license agreement on the manufacturing, registration, and sales of Rigvir medicine in the CIS (Commonwealth of Independent States) region countries. The license agreement also includes the transfer of marketing authorisation in the CIS countries. With this deal, the Rigvir group has further distanced itself from the commercialisation of the medicine and approached Biotech format with a focus on product development and further licensing.